159 related articles for article (PubMed ID: 36922784)
1. Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study.
Wada Y; Takei Y; Minezumi T; Hirashima H; Fujiwara H
BMC Womens Health; 2023 Mar; 23(1):110. PubMed ID: 36922784
[TBL] [Abstract][Full Text] [Related]
2. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
3. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
Hoshiai H; Seki Y; Kusumoto T; Kudou K; Tanimoto M
BMC Womens Health; 2021 Oct; 21(1):375. PubMed ID: 34711224
[TBL] [Abstract][Full Text] [Related]
4. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
Kawahara N; Kawaguchi R; Yamamoto K; Nishikawa K; Matsuoka M; Maehana T; Fukui Y; Yamanaka S; Sugimoto S; Iwai K; Yamada Y; Kurakami H; Hirata T; Takashima R; Suzuki S; Asada K; Kasahara M; Kimura F
Trials; 2024 Jan; 25(1):68. PubMed ID: 38243317
[TBL] [Abstract][Full Text] [Related]
5. A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy.
Sasamori Y; Takehara K; Terashima T; Onodera T; Yatsuki K; Nakagawa I; Takahashi Y; Nishida H; Ichinose T; Hiraike H; Nagasaka K
BMC Womens Health; 2021 Aug; 21(1):306. PubMed ID: 34412607
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
Kitade M; Kumakiri J; Kobori H; Murakami K
Trials; 2024 May; 25(1):343. PubMed ID: 38790029
[TBL] [Abstract][Full Text] [Related]
7. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
[TBL] [Abstract][Full Text] [Related]
8. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
[TBL] [Abstract][Full Text] [Related]
9. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
[TBL] [Abstract][Full Text] [Related]
10. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Osuga Y; Enya K; Kudou K; Hoshiai H
Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
[TBL] [Abstract][Full Text] [Related]
11. The assessment of the relationship between the vascularity of FIGO Type 4-7 leiomyomas and abnormal uterine bleeding.
Gursoy AY; Cakmak D; Akgul G; Kiseli M; Umudum H; Pabuccu R; Caglar GS
J Obstet Gynaecol; 2022 Jan; 42(1):153-157. PubMed ID: 33938365
[TBL] [Abstract][Full Text] [Related]
12. Short-term administration of oral relugolix before single-port laparoscopic-assisted vaginal hysterectomy for symptomatic uterine myomas: A retrospective comparative study with leuprorelin injection.
Takeda A
J Obstet Gynaecol Res; 2022 Jul; 48(7):1921-1929. PubMed ID: 35460303
[TBL] [Abstract][Full Text] [Related]
13. A pictorial review of ultrasonography of the FIGO classification for uterine leiomyomas.
Bajaj S; Gopal N; Clingan MJ; Bhatt S
Abdom Radiol (NY); 2022 Jan; 47(1):341-351. PubMed ID: 34581926
[TBL] [Abstract][Full Text] [Related]
14. The need for further surgical intervention following primary hysteroscopic morcellation of submucosal leiomyomas in women with abnormal uterine bleeding.
Maheux-Lacroix S; Mennen J; Arnold A; Budden A; Nesbitt-Hawes E; Won H; Abbott J
Aust N Z J Obstet Gynaecol; 2018 Oct; 58(5):570-575. PubMed ID: 29355897
[TBL] [Abstract][Full Text] [Related]
15. Relugolix for the treatment of uterine fibroids.
Barra F; Seca M; Della Corte L; Giampaolino P; Ferrero S
Drugs Today (Barc); 2019 Aug; 55(8):503-512. PubMed ID: 31461087
[TBL] [Abstract][Full Text] [Related]
16. Is a history of cesarean section a risk factor for abnormal uterine bleeding in patients with uterine leiomyoma?
Kinay T; Basarir ZO; Tuncer SF; Akpinar F; Kayikcioglu F; Koc S; Karakaya J
Saudi Med J; 2016 Aug; 37(8):871-6. PubMed ID: 27464864
[TBL] [Abstract][Full Text] [Related]
17. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
Neblett MF; Stewart EA
Obstet Gynecol; 2023 May; 141(5):901-910. PubMed ID: 37103532
[TBL] [Abstract][Full Text] [Related]
18. Relugolix for the treatment of uterine fibroids.
Rocca ML; Palumbo AR; Lico D; Fiorenza A; Bitonti G; D'Agostino S; Gallo C; Di Carlo C; Zullo F; Venturella R
Expert Opin Pharmacother; 2020 Oct; 21(14):1667-1674. PubMed ID: 32674616
[TBL] [Abstract][Full Text] [Related]
19. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
Syed YY
Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous regression of a giant uterine leiomyoma after delivery: a case report and literature review.
Zhu-Ge L; Bei Q; Pan W; Ni X
BMC Pregnancy Childbirth; 2024 Feb; 24(1):123. PubMed ID: 38341545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
